First patient recruited for Phase III Japanese acute respiratory distress syndrome trial
Faron Pharmaceuticals’ Japanese licensing partner Maruishi has recruited the first patient in the Japanese Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS), with FP-1201-lyo (Traumakine).
